Tomer Ben-Kiki - 15 Feb 2024 Form 4 Insider Report for DarioHealth Corp. (DRIO)

Role: Chief Operating Officer
Signature: /s/ Tomer Ben-Kiki
Issuer symbol: DRIO
Transactions as of: 15 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 21 Feb 2024, 16:16:56 UTC
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRIO	Stock Option (right to buy)	Award	$0	+717,947		$0.000000	717,947	15 Feb 2024	Common Stock	717,947	$2.55	Direct	F1
transaction	DRIO	Stock Option (right to buy)	Award	$0	+300,000		$0.000000	300,000	15 Feb 2024	Common Stock	300,000	$2.55	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The options vest as follows: 291,742 shares vest immediately, and the remaining 426,205 shares vest over two years in eight equal quarterly amounts, subject to subject to the Reporting Person's continued services to the Issuer on the applicable vesting date.
F2	The options vest immediately upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principals basis) for the year ending December 31, 2024, the achievement of certain operating expense targets for the years ending December 31, 2024 and December 31, 2025, the ability to generate software value from funds invested and meet product roadmap and the retention of key employees post transaction, subject in each case to the Reporting Person's continued services to the Issuer on the applicable vesting date.

Content

The options vest as follows: 291,742 shares vest immediately, and the remaining 426,205 shares vest over two years in eight equal quarterly amounts, subject to subject to the Reporting Person's continued services to the Issuer on the applicable vesting date.

The options vest immediately upon achieving certain milestones relating to the achievement of revenues (on a U.S. generally accepted account principals basis) for the year ending December 31, 2024, the achievement of certain operating expense targets for the years ending December 31, 2024 and December 31, 2025, the ability to generate software value from funds invested and meet product roadmap and the retention of key employees post transaction, subject in each case to the Reporting Person's continued services to the Issuer on the applicable vesting date.